Duke Comp Cancer Ctr Core Support Grant

杜克癌症中心核心支持补助金

• 批准号: 7591837
• 负责人: HERBERT KIM LYERLY
• 金额: $ 655.83万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7591837
• 关键词: Duke; Comp; Cancer; Ctr; Core

DESCRIPTION (provided by applicant): The Duke Comprehensive Cancer Center (DCCC) is charged and empowered to serve as the center of Duke activities in cancer and to deliver the benefits of these activities to our community and society. As a matrix center continuously supported by the National Cancer Institute (NCI) for over 31 years, the DCCC leverages Duke's basic research infrastructure with clinical oncology research excellence which is enabled by treating 4,800 new cancer patients annually, enrolling over 1,000 patients annually onto therapeutic clinical trials, and is enhanced by the presence of national oncology research resources, such as the data and statistical centers of two NCI-funded cooperative groups. These cancer research activities are supported by $48M in NCI funding (a $27 million increase from 1998) and nearly $171 million in total research funding (a $66 million increase from 1998) and are coordinate by the DCCC and forty other center, SPORE and program project grants as well as cooperative agreements. In this competitive renewal application, we request support for 358 members (an increase of 68 since 1998) working in 11 Research Programs supported by 17 Shared Resources. Significant basic scientific advances have been made by DCCC investigators including: an understanding of DNA mismatch repair mechanisms, the role of Ras structure md signaling, and the generation of novel anti-cancer agents targeting hormone receptors. These advances are balanced with clinical and population studies such as the first clinical trial demonstrating a benefit of a new class of anti-cancer compounds, the anti-angiogenesis agents and the alpha emitter 211-Astatine; the development and demonstration of the use of umbilical cord blood as a source of stem cells for transplantation; and the development and demonstration of the use of gene expression array profiling to predict clinical outcomes in breast cancer. The DCCC has benefited from a five-year fund raising campaign which generated $113 million in philanthropic support, generated new laboratory and administrative space, enabled new Programs-in-Development in Organogenesis/Stem Cell Biology and Imaging, and enabled enhancement of Shared Resources such as Bioinformatics, Tissue and Blood Procurement, and Clinical Cellular Processing. This application for support of the DCCC articulates the principles, goals and strategies for propelling the DCCC to fully leverage the enormous advances in biomedical research to improve and extend the lives of cancer patients with cancer and at risk for cancer, and delivering these to society.

描述（由申请人提供）：杜克大学综合癌症中心（DCCC）被指控并有权充当癌症杜克活动的中心，并将这些活动的好处带给我们的社区和社会。 作为国家癌症研究所（NCI）不断支持31多年的矩阵中心，DCCC利用了杜克大学的基础研究基础设施，并具有临床肿瘤学研究的卓越性，每年可通过4800名新的癌症患者治疗4800名新的癌症患者，每年招募1,000多名患者通过治疗临床试验和统计研究，并在国民统计中占据了国民统计研究，该研究的数据及其统计数据，该研究是由国民统计研究的，即统计的国家，该研究是由国民统计的。 NCI资助的合作团体。 这些癌症研究活动得到了4,800万美元的NCI资金（比1998年增长2700万美元）和近1.71亿美元的总研究资金（比1998年增加了6600万美元），并由DCCC和40个其他中心，孢子和计划项目赠款以及合作协议协调。 在此竞争性更新申请中，我们要求对358名成员（自1998年以来增加68名）的支持，在11项研究计划中，由17个共享资源支持。 DCCC研究人员已经取得了重大的基本科学进步，包括：了解DNA不匹配修复机制，RAS结构MD信号传导的作用以及针对激素受体的新型抗癌剂的产生。 这些进步在临床和人群研究中得到了平衡，例如第一次临床试验，证明了新的抗癌化合物，抗血管生成剂和Alpha Emitter 211-Astatine的好处。使用脐带血作为干细胞来源的发展和演示；以及使用基因表达阵列分析来预测乳腺癌临床结果的发展和演示。 DCCC受益于一项为期五年的筹款活动，从而产生了1.13亿美元的慈善支持，产生了新的实验室和行政空间，使在器官发生/干细胞生物学和成像中开发了新的计划，并能够增强共享资源，例如生物信息信息，组织，组织和血液采购，以及临床细胞处理。 对DCCC的支持申请表达了推动DCCC充分利用生物医学研究的巨大进步的原则，目标和策略，以改善和延长癌症患者的生命和癌症风险，并将其交付给社会。